Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Esomeprazole Magnesium Enteric-coated Suspension, indicating a significant advancement in its product portfolio [1] Group 1: Product Development - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Esomeprazole Magnesium Enteric-coated Suspension [1] - Esomeprazole is a proton pump inhibitor and the S-isomer of Omeprazole, specifically designed to inhibit gastric acid secretion by blocking the H+-K+ ATPase in gastric parietal cells [1] - The active ingredient of Esomeprazole is converted in the acidic environment of gastric parietal cells, effectively suppressing both basal and stimulated gastric acid secretion [1]

Core Viewpoint - Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Compound Polyethylene Glycol (3350) Electrolyte Powder, which is indicated for treating chronic constipation in children aged 1 to 11 years and fecal impaction in children aged 5 to 11 years [1] Group 1 - The approved drug is indicated for treating chronic constipation in children aged 1 to 11 years [1] - It is specifically used for treating fecal impaction, which is severe constipation accompanied by rectal and/or colonic fecal mass accumulation, in children aged 5 to 11 years [1] - The mechanism of action of Polyethylene Glycol 3350 is based on its osmotic effect in the intestines, with the onset of action varying depending on the severity of fecal impaction or chronic constipation [1] Group 2 - The electrolyte components of the drug are designed to maintain the balance of sodium, potassium, and water [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Esomeprazole Magnesium Enteric-coated Suspension, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Esomeprazole Magnesium Enteric-coated Suspension [1] - Esomeprazole is a proton pump inhibitor and the S-isomer of Omeprazole, which specifically inhibits the H+-K+ ATPase in gastric parietal cells, blocking the final step of gastric acid secretion [1] Group 2: Product Information - Esomeprazole is converted into its active form in the acidic environment of gastric parietal cells, providing inhibition of both basal gastric acid secretion and stimulated gastric acid secretion [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of its drug, Ketoconazole Sustained-Release Tablets, which is indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has been granted the drug registration certificate [1] - The approved drug, Ketoconazole Sustained-Release Tablets, targets peripheral vascular diseases [1] - The specific indications for the drug include intermittent claudication and rest pain [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Esomeprazole Magnesium Enteric-coated Suspension, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Esomeprazole Magnesium Enteric-coated Suspension [1] - Esomeprazole is a proton pump inhibitor and the S-isomer of Omeprazole, which specifically inhibits the H+-K+ ATPase in gastric parietal cells, blocking the final step of gastric acid secretion [1] Group 2: Product Information - Esomeprazole is converted into its active form in the acidic environment of gastric parietal cells, providing inhibition of both basal gastric acid secretion and stimulated gastric acid secretion [1]

Group 1 - The company announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Ketoconazole Sustained-Release Tablets from the National Medical Products Administration [1]

证券代码：300723 证券简称：一品红 公告编号：2025-081 一品红药业集团股份有限公司 关于全资子公司获得己酮可可碱缓释片注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州市联瑞 制药有限公司于近日收到国家药品监督管理局核准签发的关于己酮可可碱缓释 片的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：己酮可可碱缓释片 英文名/拉丁名：Pentoxifylline Sustained-release Tablets 主要成份：己酮可可碱 剂 型：片剂 注册分类：化学药品 3 类 规 格：0.4g 药品注册标准编号：YBH27652025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格： 10 片/板，1 板/盒 处方药/非处方药：处方药 上市许可持有人地址：广州市南沙区万顷沙镇同发路 2 号自编 101 栋 5 层 生产企业：广州市联瑞制药有限公司 生产企业地址：广州市南沙区万顷沙镇同发路 2 号 药品批准文号：国药准字 H20 ...

证券代码：300723 证券简称：一品红 公告编号：2025-080 一品红药业集团股份有限公司 关于全资子公司获得艾司奥美拉唑镁肠溶干混悬剂注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于艾司奥美拉唑镁 肠溶干混悬剂的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：艾司奥美拉唑镁肠溶干混悬剂 英 文 名 / 拉 丁 名 ： Esomeprazole Magnesium for Delayed-release Oral Suspension 主要成份：艾司奥美拉唑镁 剂 型：口服混悬剂 注册分类：化学药品 3 类 规 格：20mg（按 C17H19N3O3S 计）、40mg（按 C17H19N3O3S 计） 药品注册标准编号：YBH26322025 药品有效期：24 个月 申请事项：药品注册（境内生产） 包装规格： 30 袋/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管 ...

证券代码：300723 证券简称：一品红 公告编号：2025-082 一品红药业集团股份有限公司 关于全资子公司获得复方聚乙二醇（3350）电解质散注册证书的公告 一、药品注册证书主要信息 药品通用名称：复方聚乙二醇（3350）电解质散 英文名/拉丁名：Polyethylene Glycol（3350）and Electrolytes Powder 主要成份：聚乙二醇 3350，氯化钠，碳酸氢钠，氯化钾 剂 型：散剂 注册分类：化学药品 3 类 规 格：6.9g/袋 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于复方聚乙二醇 （3350）电解质散的《药品注册证书》，现将有关事项公告如下： 药品注册标准编号：YBH29192025 药品有效期：24 个月 申请事项：药品注册（境内生产） 包装规格： 14 袋/盒，28 袋/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求 ...

Core Viewpoint - The lawsuit against Yipinhong Pharmaceutical by Huiyou International, claiming 528 million yuan in damages, highlights significant risks in intellectual property management and product selection within the pharmaceutical industry in China [1][2]. Group 1: Background of the Dispute - A decade-long collaboration between Yipinhong and Huiyou International, initiated in 2014 to develop the drug Prelidil, has deteriorated due to market changes and regulatory actions [2]. - The market for Prelidil plummeted from 4.5 billion yuan in 2018 to 600 million yuan in 2019 after it was placed on a key monitoring list by the National Health Commission, leading to the cessation of their partnership [2]. Group 2: Financial Performance and Challenges - Yipinhong has faced continuous financial struggles, with a 42.07% year-on-year revenue decline in 2024 and a net loss of 540 million yuan; the first three quarters of 2025 also showed a revenue drop of 34.35% and a loss of 136 million yuan [4]. - The company was penalized for collusion in the seventh national centralized procurement, resulting in the loss of qualification for a product and a refund of 266 million yuan to healthcare insurance [4]. Group 3: Industry Implications and Management Issues - The lawsuit reveals significant management flaws in the pharmaceutical sector regarding collaboration structures, intellectual property ownership, and contract execution, particularly in a heavily regulated environment [6]. - The original valuation of the intellectual property injected into the joint venture was 88 million yuan, with the current claim being six times that amount, indicating a reassessment of technology value [6]. - The ongoing legal battle serves as a warning for the entire pharmaceutical industry about the critical importance of strategic product selection and robust intellectual property management [6].